Internal Medicine, Gastroenterology · Louisville, KY
NPI
1245643006
Since 2014
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
401 E Chestnut St Unit 310
Louisville, KY, 40202
Phone (502) 588-4710
Groups this clinician bills Medicare through
Medicare paid, 2024
$37K
389 services
Medicare patients, 2024
190
Average age 70
Drug cost, 2024
$3.2M
439 prescriptions
Company payments, 2025
$1,435
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Brandon A Wuerth was code 99233 (hospital e&m - subsequent), 101 times for 53 patients. In total Brandon A Wuerth billed 389 services in 31 codes, and Medicare paid $37K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-08-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 101 | 53 | $85.04 | $8,589 |
| 99222 Hospital E&M - Initial | Facility | 59 | 58 | $93.42 | $5,512 |
| 99223 Hospital E&M - Initial | Facility | 48 | 47 | $129.32 | $6,207 |
| 99214 Office E&M - Established | Facility | 30 | 24 | $70.34 | $2,110 |
| 99214 Office E&M - Established | Office | 25 | 25 | $75.50 | $1,888 |
| 43239 Upper GI Endoscopy | Facility | 25 | 24 | $72.03 | $1,801 |
| 45380 Lower GI Endoscopy - Other | Facility | 21 | 21 | $94.66 | $1,988 |
By year: 2022 $48K for 541 services; 2023 $55K for 572 services; 2024 $37K for 389 services.
Medicare prescription drug claims, 2024
In 2024, the drug Brandon A Wuerth prescribed most often to Medicare patients was Skyrizi On-Body (Risankizumab-Rzaa), with 57 prescriptions and refills. In total Brandon A Wuerth wrote 439 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Skyrizi On-Body Risankizumab-Rzaa | 57 | 72 | Under 11 | $1.2M |
| Stelara Ustekinumab | 38 | 51 | Under 11 | $1.2M |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 22 | 24 | Under 11 | $684 |
| Entyvio Vedolizumab | 20 | 23 | Under 11 | $181K |
| Omeprazole Generic | 20 | 41 | Under 11 | $205 |
| Dicyclomine Hcl Generic | 18 | 20 | Under 11 | $269 |
| Cholestyramine Cholestyramine (With Sugar) | 18 | 27 | Under 11 | $1,906 |
| Rinvoq Upadacitinib | 15 | 15 | Under 11 | $91K |
| Ondansetron Hcl Generic | 14 | 14 | Under 11 | $216 |
| Humira(Cf) Pen Adalimumab | 13 | 13 | Under 11 | $89K |
| Pantoprazole Sodium Generic | 13 | 37 | Under 11 | $95.87 |
| Prednisone Generic | 13 | 20 | Under 11 | $177 |
| Omvoh Pen Mirikizumab-Mrkz | 12 | 12 | Under 11 | $124K |
| Sulfasalazine Generic | 11 | 23 | Under 11 | $698 |
Brand drugs: 219 claims; generic drugs: 220 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Brandon A Wuerth $1,435 ($1,435 in general payments such as food, travel and fees) from 9 companies. The largest payer was Janssen Biotech, Inc. with $662.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 19 | $662 |
| Abbvie Inc. ABBV | 18 | $401 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 5 | $121 |
| Pfizer Inc. PFE | 4 | $70.94 |
| Ardelyx, Inc. ARDX | 3 | $53.55 |
| Lilly USA, LLC LLY | 2 | $50 |
| Organon LLC OGN | 2 | $32.65 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 1 | $24.7 |
| Celltrion USA Inc. 068270.KS | 1 | $19.7 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.